Beyond
Biological Limits
e184 is a biotechnology and neurotechnology company working to overcome the limits of human biology.
Reproduction
Reproduction has not changed in four million years. Age, anatomy, and sex still determine who can become a parent. Medicine has extended the window incrementally. Technology has barely reached it.
The global fertility rate has halved in seventy years, from 4.84 to 2.23. Today, 71% of the global population already lives in countries below replacement fertility, and 198 of 204 countries are projected to fall below replacement by 2100.
Public discussion of this decline focuses almost entirely on social and economic causes. What receives almost no attention is the parallel collapse on the biological side, where the numbers are equally staggering.
Against this trajectory, biology becomes the one driver of fertility that technology can unlock.
unborn children missing from the world today due to biological causes.
children never born each year, 34 every minute.
one unborn child
for every 10 alive.
In vitro gametogenesis
women past menopause unable to conceive.
LGBTQ+ adults unable to have children genetically related to both partners.
women of reproductive age diagnosed as infertile.
e184 develops in vitro gametogenesis to generate functional gametes from somatic cells, restoring biological parenthood across age, sex, and anatomy.
Ectogenesis
women of reproductive age affected by tubal disease, uterine factors, or recurrent pregnancy loss.
babies born preterm each year, the leading cause of death in children under five.
survival below 21 weeks. More than half of survivors at 23 weeks face lifelong disabilities.
e184 develops ectogenesis to sustain gestation outside the human body, eliminating prematurity as a cause of death, and enabling biological parenthood independent of the ability to carry a pregnancy.
Genome
The human genome carries nearly four billion years of evolution, traced back to the first ancestral cell from which all life on Earth descends. Every ancestor since has added to it: the mutations that cause disease, the variants that contribute to aging, the viral remnants and broken genes of every species and generation that came before.
It is biology’s longest record of error, and modern medicine only treats its consequences. The code itself has remained untouched.
For the first time, we are no longer bound by this inheritance. The genetic code is becoming something we read, edit, and ultimately rewrite, removing accumulated errors and shaping a genome built for health and longevity.
Genome Engineering
Almost every person carries genetic risk for disease. Hundreds of millions of people are affected by inherited disorders, while billions more live with polygenic diseases. The same code that drives disease also shapes how we age. e184 develops genome engineering in adults, removing pathogenic mutations and lowering inherited risk at its source.
A few people are born with rare protective variants: resistance to disease and genetic signatures associated with longer, healthier lifespans. Synthetic genomics makes it possible to install these deliberately, rather than leaving them to evolutionary chance.
The long-term objective is to redesign the human genome, addressing harmful genetic variants and rewriting the code against the failure modes of aging. Not treating the consequences of inherited biology, but correcting the source.
e184 works across the full spectrum of genome engineering in adults: editing pathogenic mutations, installing protective variants, and ultimately redesigning the human genome.
Cognition
For most of human history, intelligence developed within the fixed biological limits of the brain. Artificial intelligence changes this for the first time.
A brain–computer interface lets the mind work with AI without screens or keyboards, extending human cognition beyond its biological constraints.
Direct brain–AI connection today means surgery. Invasive interfaces reach only a handful of patients, and an implant will never scale to billions.
The bottleneck is the hardware. Reaching everyone requires an interface with no implants or surgery.
Brain–Computer Interface
Genetic potential for human intelligence has barely changed over the last several thousand years. Yet measured cognitive performance has risen dramatically within a single century. Global IQ scores increased by roughly 30 points, driven by literacy, education, and technology. Human cognition is shaped by its technological environment. The brain is not fixed.
Learning a new technology physically rewires the brain. Reading creates new links between visual and language systems. Abacus-trained children internalize calculation into visuospatial working memory and perform arithmetic without the physical device. The brain reorganizes itself around the tools it uses.
A brain–computer interface works the same way, but at a larger scale. Continuous interaction with a system that expands in capability allows the brain to build new pathways and forms of cognition that did not previously exist. As AI continues to advance, the mind grows with it, no longer bound by the limits of its biology. The expansion of human cognition becomes open-ended.
e184 develops a non-invasive brain–computer interface based on next-generation solid-state magnetometers, high-bandwidth sensors that detect neural activity without implants, creating a path to seamless, direct interaction between the human mind and AI.
Mission
Evolution has always decided how we reproduce, how our genes shape us, and how we think. e184 is building the technologies required to take control of evolution and overcome the limits of human biology.
In vitro gametogenesis and ectogenesis support the full reproductive cycle from cell to birth outside the human body. Genome engineering prevents inherited disease, extends healthy lifespan, and ultimately rewrites the genetic code itself. A non-invasive brain–computer interface enables direct brain–AI interaction and augments human cognition without surgery. Together, these programs span the full arc of human biology, from reproduction to the genome to cognition.
Where current medicine ends, e184 begins: with women who cannot conceive or carry a pregnancy, babies born too early to survive, and couples unable to have biological children. Reproduction should not be constrained by age, sex, anatomy, or the ability or willingness to carry a pregnancy.
Most causes of disease and aging are written into the genome, yet medicine still treats their downstream consequences. e184 develops genome engineering in adults to edit pathogenic mutations, install protective variants, and redesign the biological foundations of human longevity. Genetic disease need not be inevitable. Aging need not be a fixed outcome.
Invasive brain–computer interfaces enable direct brain–AI integration, but surgery confines the technology to a tiny fraction of humanity. To reshape how humans interact with AI, brain–computer interfaces must be non-implantable and scale to billions. e184 is building that interface, making the next leap in cognition open to everyone.
These technologies should expand human potential while preserving human identity, autonomy and fundamental values. We believe they should be universally accessible.
Medical necessity is the starting point.
Biological freedom is the destination.
Principles
Hyperfocus
Reproduction. Genome. Cognition.
The three biological foundations of being human.
Full stack
Multiple scientific disciplines.
A single in-house research operation across biology, genomics, physics, bioinformatics, materials science, and engineering.
Long horizon
The work follows the science, not market urgency.
Backed by its founder, e184 has the resources to pursue long-term scientific ambitions
Team
Careers
We are hiring biologists, geneticists, physicists, bioinformaticians, materials scientists, and engineers who want to work on the questions that will define the next chapter in human biology.
If you spent your career being told that your most ambitious idea is interesting but unfundable, talk to us. That idea is probably the reason we exist.
Leadership
Kirill EvesFounderRead bio
Kirill Eves is a technology entrepreneur whose companies span biotechnology, neurotechnology, artificial intelligence and financial infrastructure. He is the founder of e184, a biotechnology and neurotechnology company working across reproduction, genome engineering and brain–computer interfaces with a single mission: to overcome the limits of human biology. He is also Founder and CEO of Unlimit, a global financial infrastructure company powering the agentic economy across more than 180 countries, and founded 42, an AI research company developing an autonomous AI Scientist. Together, his companies aim to redefine what technology can achieve, what science can discover and what human beings can become. Eves attended Stanford Graduate School of Business and is based in London and San Francisco.
Marianna KrellChief Operating OfficerRead bio
Marianna Krell is the Chief Operating Officer of e184, responsible for strategy execution across the company. Her responsibilities include establishing operations, hiring the team, and embedding AI into scientific and business processes. She has more than 20 years of experience in international markets, from founding and scaling early-stage companies to building operational and project-management structures at multiple organizations. Her earlier career includes work in MedTech and nuclear engineering, consulting at PwC, and roles at Orange Business Services. She is certified in strategy, change management, and executive coaching. She is based in Cyprus and Oregon, USA.
Peter ZheginProgram DirectorRead bio
Peter Zhegin is the Program Director at e184, responsible for operational setup and strategic planning for the Brain–Computer Interface Program and the development of new programs. He was previously an investment manager at 7percent Ventures, a London-based deep tech fund, investing across aerospace, transportation, agriculture, and the data stack. His focus on neurotechnology grew out of his writing and angel investing. He has supported founders as an investor and mentor and lectured on entrepreneurship and venture capital at King’s College London. Zhegin holds an MSc in Management from the University of Leeds. He is based in London, United Kingdom.
Aleksei MikhalchenkoCo-Founder & Chief Scientific Officer, IVGRead bio
Aleksei Mikhalchenko is the Co-Founder and Chief Scientific Officer of e184’s In Vitro Gametogenesis Program, where he leads the development of technology to extend reproductive choice to couples who cannot conceive. Prior to e184, Mikhalchenko served as Assistant Professor and Genome Informatics Lead at Oregon Health & Science University, where his research focused on germline genome editing and somatic cell haploidization. He developed sequencing and computational approaches for analyzing single-cell DNA and applied them to advance understanding of gamete and embryo biology. Mikhalchenko holds a PhD in Life Sciences from Skoltech, with graduate training at Harvard Medical School. He is based in Portland, Oregon.
Pablo Hurtado GonzálezChief Operating Officer, IVGRead bio
Pablo Hurtado González is the Chief Operating Officer at e184’s In Vitro Gametogenesis Program, overseeing operations and technology development. He has worked in the fertility field for 15 years, at the intersection of reproductive science and biotechnology. Prior to joining e184, Hurtado González spent eight years as co-founder and Chief Scientific Officer of Conception Bio, where he led scientific strategy and helped establish the company’s position in the IVG sector. He holds a PhD in Reproductive Health from the University of Edinburgh, an MSc in Reproductive Science and Women’s Health from University College London, and an undergraduate degree in Biochemistry from the Universidad Autónoma de Madrid. He is based in San Francisco, California.
Joseph OwenChief Scientific Officer, EctogenesisRead bio
Joseph Owen is the Chief Scientific Officer of the Ectogenesis Program at e184, responsible for scientific direction, strategic planning, and operational setup. Before joining e184, he led a multidisciplinary research team at Becoming, advancing technologies for embryo development toward ectogenesis. Earlier, as a postdoctoral researcher at the University of California, San Diego, he developed experimental systems using stem cells and embryos to study the molecular and cellular mechanisms of peri-implantation development. Owen holds a PhD in Integrative Genetics and Genomics, with an emphasis on reproductive biology, from the University of California, Davis. He is based in Portland, Oregon.
Anishur RahmanCo-Founder & Chief Scientific Officer, BCIRead bio
Anishur Rahman is the Co-Founder and Chief Scientific Officer of e184’s Brain–Computer Interface Program, where he leads the development of magnetic-field sensing methods to detect brain signals for the company’s brain–computer interfaces. Before joining e184, Rahman was a Senior Research Fellow in the Department of Physics at the University of Warwick, where he developed new readout techniques for magnetometers. Earlier in his career, he conducted research at University College London on levitated nanoparticles in vacuum for applications in quantum physics and quantum optics. Rahman holds a PhD in Photonics and a Master’s in Telecommunications from the University of South Australia, and a Bachelor’s in Electrical Engineering from the Bangladesh University of Engineering and Technology (BUET). He is based in Coventry, United Kingdom.
Scientific Advisors
![Mo Ebrahimkhani]()
Mo EbrahimkhaniMD, Synthetic Biology, University of PittsburghRead bio
Mo Ebrahimkhani is an Associate Professor of Pathology and Bioengineering at the University of Pittsburgh, where he leads the Laboratory for Synthetic Morphogenetics and Tissue Ecology. His research combines synthetic developmental biology, stem cell engineering and systems biology to understand and engineer multicellular tissues for regenerative medicine. His group develops stem-cell models of human development, vascularized organoids containing multiple cell types, and programmable tissues. The team developed heX-embryoids, stem-cell-derived models that reproduce aspects of early post-implantation human development, including yolk-sac-like blood formation.
Ebrahimkhani co-developed the synthetic tissue ecology framework, which applies ecological principles to the design of multicellular systems. His work also uses computational and machine-learning methods to guide tissue engineering and organoid development. His research has appeared in Nature, Nature Medicine, Nature Cell Biology, Cell Systems and Nature Communications. His awards include the Charles E. Kaufman Foundation Initiative Award in 2021, the University of Pittsburgh’s Health Sciences Ascending Star Award in 2024, the Mayo Clinic Accelerated Regenerative Medicine Award and an EASL Sheila Sherlock Fellowship held from 2005 to 2007. Ebrahimkhani holds an MD from Tehran University of Medical Sciences and completed postdoctoral training in Biological Engineering at MIT. He is based in Pittsburgh, Pennsylvania.
![Guojun Sheng]()
Guojun ShengPhD, Developmental Biology, Kumamoto UniversityRead bio
Guojun Sheng is a professor at Kumamoto University’s International Research Center for Medical Sciences and Graduate School of Medical Sciences, where he leads the Developmental Morphogenesis laboratory. His research focuses on epithelial-to-mesenchymal transition in gastrulation and mesoderm formation, extraembryonic tissue development, and the links between these cell transitions in development and cancer. Using avian embryos, his laboratory studies how blood, vascular and smooth muscle cells develop. Before joining Kumamoto in 2015, Sheng directed the Laboratory for Early Embryogenesis at the RIKEN Center for Developmental Biology in Kobe for eleven years.
Sheng co-authored a Nature Biotechnology study, published online in 2025, that established embryonic stem cells from chicken and seven other bird species and demonstrated germline competence in chicken cells. His publications also include a 2025 Cell review on epithelial-to-mesenchymal transition and a 2021 Science review on gastrulation and the primitive streak. He leads avian conservation research supported by Revive & Restore. Sheng holds a PhD in Developmental Genetics from Rockefeller University and completed postdoctoral training in Molecular Embryology at Columbia University and University College London. He is based in Kumamoto, Japan.
![Neil Hunter]()
Neil HunterPhD, Meiosis & Chromosome Biology, UC DavisRead bio
Professor of Microbiology and Molecular Genetics at the University of California, Davis, and Howard Hughes Medical Institute Investigator, where he leads the Hunter Lab. Dr. Hunter has published extensively across genetics, cell biology, and biochemistry, with a focus on the molecular mechanisms of meiosis. His lab combines mouse, yeast, and cell, tissue, and organ culture models to understand how chromosomes are accurately distributed into gametes, with particular emphasis on homologous recombination, the DNA-repair process that meiosis adapts to drive chromosome pairing and segregation. His current work explores how genetics and environment, including sex, sexual maturation, aging, and chemical exposure, shape this essential process, with implications for infertility and cancer. In addition to his research efforts, Dr. Hunter serves as a scientific advisor with e184, providing guidance and expertise to ensure the highest likelihood of project success. Based in California.
![David Andrijevic]()
David AndrijevicMD, Neurosciences, NYU Langone HealthRead bio
David Andrijevic is a Cardiothoracic Surgery Fellow at NYU Langone Health and a researcher in organ preservation and recovery. Previously, he was an Associate Research Scientist in Nenad Sestan’s laboratory at Yale School of Medicine, where he helped develop OrganEx, a platform that combines perfusion technology with a cell-protective fluid. In a study in pigs, treatment began one hour after cardiac arrest and preserved tissue integrity, reduced cell death and restored selected cellular functions across multiple organs. Researchers also observed renewed cardiac electrical activity during perfusion and contractions in heart-muscle tissue slices collected from the treated pigs.
Andrijevic was a co-first author of the 2022 Nature paper introducing OrganEx. The study was included in the NIH’s 2022 research highlights for promising medical findings. He is also first author of a 2025 Nature Reviews Bioengineering review of mechanisms and strategies for organ recovery, with applications in resuscitation research and transplantation. Andrijevic holds an MD from the University of Osijek in Croatia and gained research experience in Germany, France, Turkey and Canada. He is based in New York City.
![Benjamin Hughes]()
Benjamin HughesPhD, Organ Preservation, DukeRead bio
Benjamin Hughes is a senior scientist at the Duke Ex Vivo Organ Laboratory, where he oversees laboratory operations and researches organ preservation and gene therapy for transplantation. His work spans neuroscience, gene therapeutics and strategies to extend organ preservation and improve graft longevity after transplantation. Hughes has co-authored studies demonstrating 24-hour kidney preservation using subnormothermic machine perfusion, with improved post-transplant function in pigs compared with static cold storage. He also co-authored research showing that gene delivery to donor lungs reduced acute cellular rejection in a rat transplant model. Hughes is a scientific adviser to e184. He is based in North Carolina.
![Daniele Faccio]()
Daniele FaccioPhD, Quantum Imaging, University of GlasgowRead bio
Daniele Faccio is Professor of Quantum Technologies at the University of Glasgow, where he leads the Extreme-Light group. He has held a Royal Academy of Engineering Chair in Emerging Technologies since 2019. His research focuses on quantum and computational imaging, including methods for seeing around corners and imaging through materials that strongly scatter light, such as biological tissue. His 2023 European Research Council Advanced Grant project, Boson Sensing and Quantum Imaging for Complex Biological Systems, develops quantum neurophotonics to investigate brain activity and structural changes associated with neurodegeneration.
Faccio is a Fellow of the Royal Society of Edinburgh and Optica. He held a Marie Curie Fellowship in 2009, and his honors include the Philip Leverhulme Prize in Physics in 2015, the Royal Society of Edinburgh Senior Public Engagement Medal and the Royal Society Wolfson Research Merit Award in 2017, and appointment as Knight of the Order of the Star of Italy. He holds a PhD in Physics from the University of Nice Sophia Antipolis in France.
![Bijan Pesaran]()
Bijan PesaranPhD, Brain–Machine Interfaces, University of PennsylvaniaRead bio
Bijan Pesaran is the Robert A. Groff Professor of Research and Teaching in Neurosurgery II and Professor of Neuroscience and Bioengineering at the University of Pennsylvania. His laboratory studies how neural populations in different brain regions coordinate decisions and action, while developing devices and algorithms to record from and influence those networks. He was the first to report that movement intentions could be decoded from local field potentials with accuracy comparable to single-neuron recordings, work reflected in his 1999 patent and 2002 paper that helped pave the way for a new generation of less invasive neural interfaces. His work has identified mechanisms linking frontal and parietal cortex during coordinated eye and hand movements and now spans non-human-primate experiments and first-in-human research on brain interfaces.
A member of the Simons Collaboration on the Global Brain, Pesaran’s publications have received more than 11,300 citations, with a Google Scholar h-index of 44. He is named on at least five granted U.S. patents related to neural prosthetics and neural-signal decoding. He received the National Science Foundation CAREER Award in 2010, the McKnight Scholar Award from the McKnight Endowment Fund for Neuroscience in 2008, an Alfred P. Sloan Foundation Research Fellowship in 2007 and a Burroughs Wellcome Fund Career Award in the Biomedical Sciences in 2004. Based in Philadelphia, he holds a B.A. (Hons) in Physics and Theoretical Physics from the University of Cambridge and a Ph.D. in Physics from the California Institute of Technology.
Research & Engineering
![Victoria Roberts]()
Victoria RobertsHead of Placenta Biology, EctogenesisRead bio
Victoria Roberts is the Head of Placenta Biology at e184, where she leads the development of the company’s placentation program and the scientific team advancing its research strategy. She brings more than two decades of expertise in placental biology, with a particular focus on understanding placental function across pregnancy and translating insights from in vivo and in vitro models into new experimental approaches. Prior to joining e184, Roberts held a faculty position at Oregon Health & Science University and spent 17 years at the Oregon National Primate Research Center, where she led research using pregnant nonhuman primates to investigate placental function. Her work has included the development and validation of advanced in vivo imaging technologies, as well as extensive experience in cell and tissue culture, including a placenta organoid model system. Roberts earned her PhD in placental physiology from the University of Manchester, UK, followed by postdoctoral research at the University of Cincinnati. She is based in Portland, Oregon.
Chao-Shun YangTeam LeadRead bio
Chao-Shun Yang is the Science Team Lead for Cellular Reprogramming at e184’s In Vitro Gametogenesis Program. He has more than 12 years of experience across academia, biotech, and clinical research, focused on early-stage drug discovery through iPSC-derived models, phenotypic assays, and machine learning. At insitro, Yang developed mechanistic assay platforms and led teams that delivered validated targets in MASLD. He holds a PhD in Biochemistry and Molecular Pharmacology from UMass Chan Medical School and carried out postdoctoral research at UC San Diego, where he used iPSC technology to investigate the mechanistic drivers of Alzheimer’s disease. He is based in Portland, Oregon.
Nuria Martí GutiérrezLead EmbryologistRead bio
Nuria Martí Gutiérrez is the Lead Embryologist at e184’s In Vitro Gametogenesis Program. Prior to joining e184, she spent 14 years as a Staff Scientist and Lab Manager at Oregon Health & Science University, where her work spanned reproductive genomics, germline modification, and in vitro gametogenesis. She holds a PhD in reproductive technologies from the University of Valencia and a Master’s in Clinical Biology and Reproduction from the University of Alicante. She is based in Portland, Oregon.
![Mariyan Jeyarajah]()
Mariyan JeyarajahSenior Scientist, Trophoblast Biology, EctogenesisRead bio
Mariyan Jeyarajah is a Senior Scientist in the Ectogenesis Program at e184, specializing in early placental development and trophoblast biology. Prior to joining e184, Mariyan served as a Scientist at Conception Biosciences, where he developed and optimized protocols for stem cell differentiation. He earned his PhD in Anatomy and Cell Biology from the University of Western Ontario in Canada, where his research focused on elucidating the roles of transcriptional regulators in the development of the human and mouse placenta.
![Ben Kiratitanaporn]()
Ben KiratitanapornSenior Scientist, Biomaterials Development, EctogenesisRead bio
Ben Kiratitanaporn is a Senior Scientist in the Ectogenesis Program at e184, specializing in advanced functional biomaterials development. Prior to joining e184, he was an Associate Staff Scientist at Cincinnati Children's Hospital Medical Center, developing bioengineered intestinal microphysiological systems (MPS). He earned his PhD in Bioengineering from the University of California San Diego, where his research centered on biomaterials development and 3D bioprinting for musculoskeletal tissue engineering.
Scott BarishScientistRead bio
Scott Barish is a Scientist at e184’s In Vitro Gametogenesis Program, working on epigenetic reprogramming. He has more than 10 years of experience across academia and industry. He was a Genome Engineering Scientist at Colossal Biosciences, where he developed cell and genome engineering technologies, and previously held a postdoctoral fellowship at Baylor College of Medicine, studying nervous system development and rare genetic disorders. Barish holds a PhD in Biology from Duke University, where he studied the development of the olfactory system in Drosophila, and a BA in Biology from Hampshire College. He is based in Portland, Oregon.
Minoo KarimiScientistRead bio
Minoo Karimi is a Scientist at e184’s In Vitro Gametogenesis Program, developing genome engineering strategies for human pluripotent stem cells, with applications in cell therapy. Her work focuses on CRISPR genome editing, stem cell engineering, cell line development, and assay optimization. Prior to joining e184, Karimi led work on mRNA synthesis and delivery platforms at STEMCELL Technologies and was scientific lead for the development and commercialization of an mRNA-based forward programming kit. She holds a PhD in Genetics from RIKEN affiliated with Saitama University in Japan and carried out postdoctoral work at the Université de Montréal. She is based in Portland, Oregon.
Dongkyeong KimScientistRead bio
Dongkyeong Kim is a Scientist at e184’s In Vitro Gametogenesis Program, developing platforms in chromatin biology and gene regulation. He has more than a decade of research experience across molecular biology, neuroscience, and genetic medicine, focused on engineering therapeutic tools. Kim held positions at the Albert Einstein College of Medicine and Epitor Therapeutics. His work includes the design of all-in-one AAV vector systems, enhancer-targeting strategies, and ultracompact CRISPR systems. Kim holds a PhD from Chung-Ang University in Seoul, South Korea, and carried out postdoctoral work at the State University of New York at Buffalo. He is based in Portland, Oregon.
Yingzhen PeiScientistRead bio
Yingzhen Pei is a Scientist at e184’s In Vitro Gametogenesis Program, working on large-scale genetic screening. He has five years of experience in high-throughput screening and eight years in mammalian in vitro differentiation. His work identified factors required for motor neuron differentiation and explained why ZBTB11 and ZFP131 maintain pluripotency. Pei holds a PhD in Biology from New York University and a Bachelor of Science from Peking University. He is based in Portland, Oregon.
![Tyler Allen Mayes]()
Tyler Allen MayesAssay Development ScientistRead bio
Tyler Allen Mayes is an Assay Development Scientist at e184, where he leads the development of shared assay pipelines, coordinating work across research teams to support multiple projects. Before joining e184, Mayes spent several years as a Genome Engineer at Colossal Biosciences, where he specialized in prime editing and large gene insertion and developed sequencing pipelines. His earlier research explored metabolic engineering of methanogens as potential living carbon sinks for biomaterial production. He also studied the genetics of nitrogen-fixing plant-bacteria symbioses, with the aim of developing self-fertilizing crops. Mayes holds a BS in Molecular Biology and Genetics from the University of North Texas. He is pursuing a master’s degree in Biotechnology and Business Development at Harvard Extension School. He is based in Portland, Oregon.
![Menaka Sanghvi]()
Menaka SanghviScientist, EctogenesisRead bio
Menaka Sanghvi is a Scientist in the Ectogenesis Program at e184, where she leads the development and application of computational approaches to support the research across the program. She earned her PhD in Genetics, Developmental, and Disease at the University of Texas Southwestern Medical Center. Her doctoral research integrated transcriptomics, proteomics, computational biology, CRISPR-based genome engineering, and human stem cell models to investigate the gene regulatory networks governing early human development. She joins e184 with experience in both biotech and academia, where she has combined experimental and computational approaches to characterize cellular behavior, evaluate biological perturbations, and generate data that informs therapeutic discovery and development.
![Ria Shah]()
Ria ShahScientist, Functional Genomics, EctogenesisRead bio
Ria Shah is a Functional Genomics Scientist at e184, where she leads the design and execution of next-generation sequencing strategies to support early development research. Prior to joining e184, she spent five years at Mammoth Biosciences leading NGS Core operations, assay development, and CRISPR-Cas off-target discovery pipelines. She holds a B.S. in Biochemistry and Molecular Biology from the University of California, Davis and specializes in assay development, high-throughput screening, and multi-omic technologies.
Tassilo NeubauerBioinformatics EngineerRead bio
Tassilo Neubauer is a Bioinformatics Engineer at e184’s In Vitro Gametogenesis Program. He moved into bioinformatics from software engineering and worked as a freelance bioinformatics consultant before joining e184. Neubauer holds a Bachelor’s in Computer Science from the Karlsruhe Institute of Technology in Germany, with research experience in machine learning, AI alignment, and genomic imprinting. He is based in Portland, Oregon.
![Laura-Maria Oja]()
Laura-Maria OjaAssociate Scientist, Stem Cell Biology, EctogenesisRead bio
Laura-Maria Oja is an Associate Scientist in the Ectogenesis Program at e184, where she focuses on developing stem cell models of early embryogenesis. Prior to joining e184, she worked at BrainXell Therapeutics on the development of autologous cell therapies for central nervous system diseases. She also supported iPSC-based research into neurodegenerative disease modeling at the Icahn School of Medicine. Earlier in her career, Estonian-native Oja completed her graduate studies at Kennesaw State University, where she was developing a novel delivery system for reprogramming factors to induce pluripotency in mouse embryonic fibroblasts. She holds an MSc in Biochemistry from Kennesaw State University in Georgia.
Sushma RamResearch AssociateRead bio
Sushma Ram is a Research Associate on the Epigenetic Reprogramming team at e184’s In Vitro Gametogenesis Program. She establishes and optimizes stem cell culture platforms and protocols. Before joining e184, she worked on assay development, differentiation, and gene editing for allogeneic cell therapy, developing CAR-T cells at Imugene and CAR-iNK cells at Caribou Biosciences. Ram holds a Master’s in Biomedical Engineering from Johns Hopkins University and a BTech in Biotechnology from PES University in Bangalore. She is based in Portland, Oregon.
Sarah BoltonLab Operations ManagerRead bio
Sarah Bolton is the Lab Operations Manager at e184’s In Vitro Gametogenesis Program, responsible for establishing and maintaining lab operational procedures at the company’s site in Portland, Oregon. Before joining e184, she worked as a scientist and lab manager at ALX Oncology, where her team advanced an ADC candidate through IND submission to the FDA. Her doctoral research developed chemical tools to study biological sulfur species, including methods to deliver elemental sulfur to cells and investigate its protective effects in cellular models of oxidative stress. She holds a PhD in Chemistry from the University of Oregon and a Bachelor’s in Biochemistry from California Polytechnic State University. She is based in Portland, Oregon.
![Fernanda Ordoñez Jimenez]()
Fernanda Ordoñez JimenezSenior AssociateRead bio
Fernanda Ordoñez Jimenez is a Senior Associate at e184, supporting strategic planning, management, and recruitment, with a focus on reproductive technologies. Before joining e184, she worked in venture capital in the health sector across the APAC region with Heal Venture Lab and on business transformation at Capgemini. She has research experience at the Institut Pasteur of Shanghai and Fudan University, focused on population genomics and the evolution and clonal structure of Helicobacter pylori in the context of gastric cancer. She holds a Master of Science in Computational Genetics, with a focus on Statistical Genetics. She is based in Mexico City, Mexico.
![Sofia Kozlova]()
Sofia KozlovaAnalystRead bio
Sofia Kozlova is an Analyst at e184’s Brain–Computer Interface Program, supporting strategic planning and assessing the state of the art across sensor engineering, solid-state physics, neuroscience, and machine learning. She has a background in biomedical engineering, with laboratory experience in synthetic chemistry, drug delivery systems, and computational research. Kozlova has contributed to published work on neurodevelopment and HIV, and has presented research on modeling subcutaneous drug delivery with hydrogels and on computational modeling of drug receptors. She is pursuing a BS in Chemical Engineering with an additional major in Biomedical Engineering at Carnegie Mellon University. She is based in Pittsburgh, Pennsylvania.
![Advay Pawar]()
Advay PawarSenior Engineer, Biomedical, EctogenesisRead bio
Advay Pawar is a Senior Engineer in the Ectogenesis Program at e184, where his work focuses on developing the oxygenation, nutrient delivery, and metabolic waste removal systems and hardware that enable the ex utero perfusion platform. Advay holds a PhD in Industrial & Systems Engineering from North Carolina State University, where his research focused on the development of tissue-engineered orthopedic implants. He also holds bachelor’s and master’s degrees in Mechanical Engineering and has industry experience in additive manufacturing from Renishaw USA and CMTI, India. He is based in Vancouver, WA.
![Yazhi Sun]()
Yazhi SunSenior Engineer, Microfluidics and Perfusion Interfaces, EctogenesisRead bio
Yazhi Sun is a Senior Engineer in the Ectogenesis Program at e184, where she is responsible for developing microfluidic and perfusion platforms to support long-term tissue culture. Before joining e184, she led bioreactor development to support the culture of bioprinted liver tissue as a postdoctoral researcher at the University of California, San Diego. She holds a PhD in NanoEngineering from the University of California, San Diego, with a focus on bioprinting and biofabrication; an MPH in Environmental Health Sciences from Yale University; and a BE in Biomedical Engineering from Peking University, China. She is based in Vancouver, Washington.